Connect your AI

Opus Genetics IRD Prepaid & Other Current

Prepaid & Other Current at other companies

AbbVieABBV

$150M-97.3%

4D Molecular TherapeuticsFDMT

$14.47M+30.0%

Opko HealthOPK

$49.45M-9.2%

Kodiak Sciences IncKOD

$5.73M+49.4%

Regeneron PharmaceuticalsREGN

$620.9M+32.4%

RegenxbioRGNX

$11.54M+4.0%

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's prepaid & other current?: Opus Genetics (IRD) reported prepaid & other current of $3.93M in Q1 2026.
How has Opus Genetics's prepaid & other current changed year-over-year?: Opus Genetics's prepaid & other current increased by 184.6% year-over-year, from $1.38M to $3.93M.
What is the long-term trend for Opus Genetics's prepaid & other current?: Over 5 years (2020 to 2025), Opus Genetics's prepaid & other current has grown at a 7.1% compound annual growth rate (CAGR), from $1.27M to $1.79M.
What does prepaid & other current mean?: Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.